Microbiome within Primary Tumor Tissue from Renal Cell Carcinoma May Be Associated with PD-L1 Expression of the Venous Tumor Thrombus

Objective To perform a proof of concept microbiome evaluation and PD-L1 expression profiling in clear-cell renal cell carcinoma (cc-RCC) with associated tumor thrombus (TT). Methods After IRB approval, six patients underwent radical nephrectomy (RN) with venous tumor thrombectomy (VTT). We collected fresh tissue specimens from normal adjacent, tumor, and thrombus tissues. We utilized RNA sequencing to obtain PD-L1 expression profiles and perform microbiome analysis. Statistical assessment was performed using Student's t-test, chi-square, and spearman rank correlations using SPSS v25. Results We noted the tumor thrombus to be mostly devoid of diverse microbiota. A large proportion of Staphylococcus epidermidus was detected and unknown if this is a surgical or postsurgical contaminant; however, it was noted more in the thrombus than other tissues. Microbiome diversity profiles were most abundant in the primary tumor compared to the thrombus or normal adjacent tissue. Differential expression of PD-L1 was examined in the tumor thrombus to the normal background tissue and noted three of the six subjects had a threshold above 2-fold. These three similar subjects had foreign microbiota that are typical residents of the oral microbiome. Conclusion Renal tumors have more diverse microbiomes than normal adjacent tissue. Identification of resident oral microbiome profiles in clear-cell renal cancer with tumor thrombus provides a potential biomarker for thrombus response to PD-L1 inhibition.

[1]  Yidong Chen,et al.  Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. , 2019, Urology.

[2]  O. Kallioniemi,et al.  Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient‐derived cancer cells , 2018, International journal of cancer.

[3]  J. López,et al.  The Impact of Tumor Eco-Evolution in Renal Cell Carcinoma Sampling , 2018, Cancers.

[4]  Zoltan Szallasi,et al.  Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal , 2018, Cell.

[5]  B. Helmink,et al.  The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. , 2018, Cancer cell.

[6]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[7]  Julia L. Drewes,et al.  High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia , 2017, npj Biofilms and Microbiomes.

[8]  J. Terzic,et al.  The urinary microbiome associated with bladder cancer , 2017, bioRxiv.

[9]  C. Fan,et al.  Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. , 2017, Cancer research.

[10]  A. Eggermont,et al.  Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Ling Xia,et al.  Fusobacterium Nucleatum Subspecies Animalis Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors , 2017, Cancer Prevention Research.

[12]  J. Bellmunt,et al.  New treatment options for metastatic renal cell carcinoma , 2017, ESMO Open.

[13]  P. Ascierto,et al.  Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment , 2016, Oncotarget.

[14]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[15]  M. Lathrop,et al.  Precision medicine from the renal cancer genome , 2016, Nature Reviews Nephrology.

[16]  Arun Z. Thomas,et al.  The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma , 2016, Therapeutic advances in urology.

[17]  M. Kortylewski,et al.  Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors , 2015, Clinical Cancer Research.

[18]  V. Margulis,et al.  Oncologic outcomes following surgical resection of renal cell carcinoma with inferior vena caval thrombus extending above the hepatic veins: a contemporary multicenter cohort. , 2014, The Journal of urology.

[19]  Allyson L. Byrd,et al.  Biogeography and individuality shape function in the human skin metagenome , 2014, Nature.

[20]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[21]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[22]  M. Meng,et al.  Natural history of untreated renal cell carcinoma with venous tumor thrombus. , 2013, Urologic oncology.

[23]  Quinn Snell,et al.  Pathoscope: Species identification and strain attribution with unassembled sequencing data , 2013, Genome research.

[24]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[25]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[26]  J. Brugarolas,et al.  The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. , 2011, European urology.

[27]  J. Brugarolas,et al.  1771 THE IMPACT OF TARGETED MOLECULAR THERAPIES ON THE LEVEL OF RENAL CELL CARCINOMA VENA CAVAL TUMOR THROMBUS , 2011 .

[28]  M. Soloway,et al.  Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombectomy: single-center experience. , 2010, European urology.

[29]  H. Sørensen,et al.  The prognostic impact of comorbidities on renal cancer, 1995 to 2006: a Danish population based study. , 2009, The Journal of urology.

[30]  K. Bensalah,et al.  Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. , 2009, European urology.

[31]  S. Boyd,et al.  Vena Caval Involvement by Renal Cell Carcinoma: Surgical Resection Provides Meaningful Long‐Term Survival , 1989, Annals of surgery.

[32]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.